The office gazette of Paris
The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese adults. Eli Lilly plans to launch the drug in India by 2025, pending approvals. The treatment is expected to be a breakthrough by aiding weight reduction, which in turn improves breathing during sleep.
Virat Kohli is poised to surpass Rahul Dravid’s Test run record against Australia in the upcoming Brisbane Test. Meanwhile, Shubman Gill aims to overtake Yuvraj […]
Delhi Police’s Crime Branch has detained Kajal Khatri for her involvement in the murder of an airline crew member in Noida. Khatri, who is married […]
The BAPS Shri Swaminarayan Mandir in Sacramento, California was vandalized with anti-Hindu messages, echoing a recent incident in New York. The Hindu American Foundation and […]